A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

December 31, 2029

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG

DZD8586

Orally, 50 mg, once daily until treatment discontinuation criterion is met.

DRUG

Bendamustine

Administered intravenously

DRUG

Idelalisib

Administered orally

DRUG

Rituximab

Administered intravenously